title: Antimicrobial treatment of Capnocytophaga infections.
abstract: Capnocytophaga spp. are normal inhabitants of the oropharyngeal flora. They are also involved in periodontal diseases or animal bites, complicated by septicaemia with dissemination to a great variety of sites, both in immunocompetent and immunocompromised hosts. This review will focus on their pathogenesis, spectrum of clinical infections and susceptibility to disinfectants and antibiotics. The spread of beta-lactamase-producing strains limits the use of beta-lactams as first-line treatments, underlying the necessity to test the in vitro susceptibility of clinical strains. Many antimicrobial treatments have been used, despite an absence of randomised studies and guidelines regarding the duration of treatment according to infected sites. Imipenem/cilastatin, clindamycin or beta-lactamase inhibitor combinations are always effective and their use can be recommended in all infections.
authors.affiliation: Equipe Microbiologie, UPRES-EA 1254, CHU Pontchaillou Rennes et Université de Rennes I, 2 avenue du Professeur Léon Bernard, 35043 Rennes Cedex, France. anne.gougeon@univ-rennes1.fr
authors.forename: Anne
authors.initials: A
authors.lastname: Jolivet-Gougeon
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Sixou
authors.forename: Zohreh
authors.initials: Z
authors.lastname: Tamanai-Shacoori
authors.forename: Martine
authors.initials: M
authors.lastname: Bonnaure-Mallet
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D002206:Capnocytophaga / Q000187:drug effects / Q000472:pathogenicity*; D015377:Cilastatin / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000209:etiology; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016867:Immunocompromised Host; D008826:Microbial Sensitivity Tests; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000187:drug effects / Q000378:metabolism; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D015377:Cilastatin; D002981:Clindamycin; D015378:Imipenem; D001618:beta-Lactamases